1. Volume 123, Issue 5, Pages 1480-1487 (May 2003)
Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma 
Lalloo Umesh G. , MD, FCCP, Malolepszy Jóseph , MD, Kozma Dezsó , MD, Krofta Kamil , MD, Ankerst Jaro , MD, Johansen Bjørn , MD, Thomson Neil C. , FRCP 
CHEST 
Volume 123, Issue 5, Pages (May 2003)
DOI: /chest
Copyright © 2003 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Change in morning (top, a) and evening (bottom, b) PEF rate during 12 weeks of treatment (0 to 90 days) with either budesonide/formoterol, 80 μg/4.5 μg bid, or budesonide alone, 200 μg bid, in adults with asthma not fully controlled on low-dose inhaled corticosteroids alone. All patients received inhaled budesonide, 100 μg bid, during the run-in period (day − 10 to day 0).
CHEST  , DOI: ( /chest )
Copyright © 2003 The American College of Chest Physicians Terms and Conditions

3. Figure 2
Change in asthma-control days during 12 weeks of inhaled treatment (0 to 90 days) with either budesonide/formoterol, 80 μg/4.5 μg bid, or budesonide alone, 200 μg bid, in adults with asthma not fully controlled on low-dose inhaled corticosteroids alone. All patients received inhaled budesonide, 100 μg bid, during the run-in period (day − 10 to day 0).
CHEST  , DOI: ( /chest )
Copyright © 2003 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Probability of patients remaining free from a mild exacerbation during 12 weeks of treatment with budesonide/formoterol, 80 μg/4.5 μg bid, or budesonide alone, 200 μg bid (Kaplan-Meier survival curves).
CHEST  , DOI: ( /chest )
Copyright © 2003 The American College of Chest Physicians Terms and Conditions